Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | GERN |
---|---|---|
09:32 ET | 38768 | 3.64 |
09:34 ET | 11401 | 3.6349 |
09:36 ET | 5500 | 3.64 |
09:38 ET | 2529 | 3.6305 |
09:39 ET | 7879 | 3.625 |
09:41 ET | 128013 | 3.605 |
09:43 ET | 38661 | 3.6 |
09:45 ET | 41775 | 3.595 |
09:48 ET | 129164 | 3.615 |
09:50 ET | 85566 | 3.605 |
09:52 ET | 31339 | 3.5999 |
09:54 ET | 81073 | 3.605 |
09:56 ET | 17641 | 3.595 |
09:57 ET | 75641 | 3.605 |
09:59 ET | 53314 | 3.625 |
10:01 ET | 10556 | 3.625 |
10:03 ET | 20148 | 3.615 |
10:06 ET | 8570 | 3.63 |
10:08 ET | 16732 | 3.635 |
10:10 ET | 7600 | 3.635 |
10:12 ET | 10428 | 3.64 |
10:14 ET | 27551 | 3.665 |
10:15 ET | 2998 | 3.68 |
10:17 ET | 83329 | 3.645 |
10:19 ET | 85584 | 3.645 |
10:21 ET | 6031 | 3.64 |
10:24 ET | 69009 | 3.64 |
10:26 ET | 8724 | 3.635 |
10:28 ET | 1697 | 3.635 |
10:30 ET | 1845 | 3.6309 |
10:32 ET | 48251 | 3.621 |
10:33 ET | 8873 | 3.625 |
10:35 ET | 63069 | 3.63 |
10:37 ET | 1600 | 3.625 |
10:39 ET | 53300 | 3.63 |
10:42 ET | 1717 | 3.62 |
10:44 ET | 13862 | 3.615 |
10:46 ET | 920 | 3.611 |
10:48 ET | 94732 | 3.605 |
10:50 ET | 895 | 3.605 |
10:51 ET | 4060 | 3.605 |
10:53 ET | 23234 | 3.59 |
10:55 ET | 33651 | 3.59 |
10:57 ET | 600 | 3.59 |
11:00 ET | 4532 | 3.59 |
11:02 ET | 33389 | 3.59 |
11:04 ET | 2263 | 3.5988 |
11:06 ET | 5045 | 3.595 |
11:08 ET | 2300 | 3.595 |
11:09 ET | 11360 | 3.6 |
11:11 ET | 2250 | 3.59 |
11:13 ET | 5475 | 3.595 |
11:15 ET | 26144 | 3.6 |
11:18 ET | 99447 | 3.63 |
11:20 ET | 50594 | 3.61 |
11:22 ET | 15072 | 3.605 |
11:24 ET | 19581 | 3.605 |
11:26 ET | 11971 | 3.6 |
11:27 ET | 9051 | 3.595 |
11:29 ET | 300 | 3.595 |
11:31 ET | 37332 | 3.595 |
11:33 ET | 7096 | 3.595 |
11:36 ET | 6552 | 3.6 |
11:38 ET | 2200 | 3.595 |
11:40 ET | 7787 | 3.5999 |
11:42 ET | 2650 | 3.595 |
11:44 ET | 6135 | 3.6 |
11:45 ET | 8912 | 3.595 |
11:47 ET | 1100 | 3.595 |
11:49 ET | 736 | 3.595 |
11:51 ET | 1252 | 3.595 |
11:54 ET | 11345 | 3.6 |
11:56 ET | 2434 | 3.595 |
11:58 ET | 1219 | 3.595 |
12:00 ET | 1136 | 3.6 |
12:02 ET | 2737 | 3.595 |
12:03 ET | 2536 | 3.595 |
12:05 ET | 1000 | 3.6 |
12:07 ET | 174303 | 3.6 |
12:09 ET | 44420 | 3.595 |
12:12 ET | 32890 | 3.585 |
12:14 ET | 21572 | 3.59 |
12:16 ET | 1699 | 3.585 |
12:18 ET | 3799 | 3.585 |
12:20 ET | 300 | 3.585 |
12:21 ET | 49701 | 3.589 |
12:23 ET | 7410 | 3.585 |
12:25 ET | 535 | 3.59 |
12:27 ET | 1231 | 3.585 |
12:30 ET | 3907 | 3.585 |
12:32 ET | 700 | 3.59 |
12:34 ET | 1330 | 3.5851 |
12:36 ET | 1037 | 3.585 |
12:38 ET | 35152 | 3.575 |
12:39 ET | 8631 | 3.58 |
12:41 ET | 4063 | 3.57 |
12:43 ET | 53955 | 3.56 |
12:45 ET | 28689 | 3.555 |
12:48 ET | 84020 | 3.54 |
12:50 ET | 100263 | 3.54 |
12:52 ET | 77361 | 3.535 |
12:54 ET | 23200 | 3.535 |
12:56 ET | 2500 | 3.535 |
12:57 ET | 12531 | 3.53 |
12:59 ET | 22483 | 3.53 |
01:01 ET | 4204 | 3.53 |
01:03 ET | 34006 | 3.525 |
01:06 ET | 39959 | 3.525 |
01:08 ET | 155800 | 3.535 |
01:10 ET | 15264 | 3.53 |
01:12 ET | 6337 | 3.52 |
01:14 ET | 43257 | 3.52 |
01:15 ET | 151082 | 3.5045 |
01:17 ET | 2043 | 3.505 |
01:19 ET | 2085 | 3.5 |
01:21 ET | 1222 | 3.5 |
01:24 ET | 22791 | 3.5 |
01:26 ET | 42430 | 3.49 |
01:28 ET | 3076 | 3.495 |
01:30 ET | 4574 | 3.49 |
01:32 ET | 13539 | 3.485 |
01:33 ET | 5838 | 3.4801 |
01:35 ET | 3887 | 3.48 |
01:37 ET | 195903 | 3.49 |
01:39 ET | 10453 | 3.485 |
01:42 ET | 20822 | 3.47 |
01:44 ET | 24807 | 3.4699 |
01:46 ET | 83898 | 3.48 |
01:48 ET | 8952 | 3.49 |
01:50 ET | 6214 | 3.5 |
01:51 ET | 26692 | 3.49 |
01:53 ET | 10787 | 3.495 |
01:55 ET | 500 | 3.5 |
01:57 ET | 35100 | 3.49 |
02:00 ET | 29145 | 3.485 |
02:02 ET | 4387 | 3.48 |
02:04 ET | 14954 | 3.47 |
02:06 ET | 8076 | 3.47 |
02:08 ET | 42089 | 3.47 |
02:09 ET | 85030 | 3.4712 |
02:11 ET | 25538 | 3.46 |
02:13 ET | 445 | 3.46 |
02:15 ET | 115905 | 3.485 |
02:18 ET | 2157 | 3.48 |
02:20 ET | 17567 | 3.475 |
02:22 ET | 22079 | 3.475 |
02:24 ET | 14078 | 3.46 |
02:26 ET | 50636 | 3.475 |
02:27 ET | 23484 | 3.4983 |
02:29 ET | 54041 | 3.5 |
02:31 ET | 9548 | 3.495 |
02:33 ET | 9814 | 3.5 |
02:36 ET | 23508 | 3.5 |
02:38 ET | 22240 | 3.5 |
02:40 ET | 5442 | 3.5 |
02:42 ET | 180935 | 3.495 |
02:44 ET | 17792 | 3.49 |
02:45 ET | 26468 | 3.49 |
02:47 ET | 62525 | 3.495 |
02:49 ET | 28218 | 3.495 |
02:51 ET | 13651 | 3.495 |
02:54 ET | 72749 | 3.495 |
02:56 ET | 12384 | 3.495 |
02:58 ET | 57448 | 3.495 |
03:00 ET | 27283 | 3.5 |
03:02 ET | 54353 | 3.5 |
03:03 ET | 123036 | 3.525 |
03:05 ET | 15361 | 3.54 |
03:07 ET | 23545 | 3.5301 |
03:09 ET | 3989 | 3.54 |
03:12 ET | 128445 | 3.51 |
03:14 ET | 30146 | 3.5 |
03:16 ET | 9091 | 3.505 |
03:18 ET | 7982 | 3.5 |
03:20 ET | 10603 | 3.505 |
03:21 ET | 57453 | 3.49 |
03:23 ET | 10829 | 3.49 |
03:25 ET | 6643 | 3.5 |
03:27 ET | 22149 | 3.495 |
03:30 ET | 11432 | 3.495 |
03:32 ET | 243852 | 3.5 |
03:34 ET | 17350 | 3.5 |
03:36 ET | 131770 | 3.495 |
03:38 ET | 7245 | 3.495 |
03:39 ET | 8002 | 3.495 |
03:41 ET | 7855 | 3.495 |
03:43 ET | 11784 | 3.495 |
03:45 ET | 29920 | 3.505 |
03:48 ET | 12814 | 3.51 |
03:50 ET | 152161 | 3.505 |
03:52 ET | 62331 | 3.495 |
03:54 ET | 24776 | 3.49 |
03:56 ET | 330570 | 3.49 |
03:57 ET | 52694 | 3.485 |
03:59 ET | 302433 | 3.49 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Geron Corp | 2.2B | -10.1x | --- |
Vera Therapeutics Inc | 2.1B | -18.2x | --- |
CG Oncology Inc | 2.1B | -26.6x | --- |
Rocket Pharmaceuticals Inc | 2.0B | -7.6x | --- |
Janux Therapeutics Inc | 2.4B | -35.1x | --- |
Keros Therapeutics Inc | 1.8B | -9.6x | --- |
Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical trial, named IMpactMF, in relapsed/refractory myelofibrosis (MF) with overall survival as the primary endpoint, that is enrolling patients. It is also conducting a Phase 1 combination therapy clinical trial, named IMproveMF, in first-line Intermediate-1, Intermediate-2 or High-Risk myelofibrosis, or frontline MF, that is enrolling patients and imetelstat is being studied in an investigator-led Phase 2 clinical trial, named IMpress, in Intermediate-2 or High-Risk myelodysplastic syndromes and acute myeloid leukemia.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.2B |
---|---|
Revenue (TTM) | $520.0K |
Shares Outstanding | 593.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.43 |
EPS | $-0.35 |
Book Value | $0.46 |
P/E Ratio | -10.1x |
Price/Sales (TTM) | 4,174.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -40,381.92% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.